Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H18ClN.ClH |
| Molecular Weight | 296.235 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@@H](CC1=CC=CC=C1)NCC2=C(Cl)C=CC=C2
InChI
InChIKey=ASTCUURTJCZRSC-ZOWNYOTGSA-N
InChI=1S/C16H18ClN.ClH/c1-13(11-14-7-3-2-4-8-14)18-12-15-9-5-6-10-16(15)17;/h2-10,13,18H,11-12H2,1H3;1H/t13-;/m0./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H18ClN |
| Molecular Weight | 259.774 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18500382Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9987865 | https://www.ncbi.nlm.nih.gov/pubmed/9050090
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18500382
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9987865 | https://www.ncbi.nlm.nih.gov/pubmed/9050090
Clobenzorex is a central stimulant and sympathomimetic used as an anti-obesity drug; an n-substituted amphetamine, which is metabolized to amphethamine. Its actions are like those of dexamphetamine and has been used as a drug of abuse.
CNS Activity
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.777 ng/mL |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.429 ng/mL |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.777 ng × h/mL |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.076 ng × h/mL |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
15.002 h |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.118 h |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
210 mg 3 times / day multiple, oral Higher than recommended Dose: 210 mg, 3 times / day Route: oral Route: multiple Dose: 210 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Disc. AE: Congestive cardiomyopathy... AEs leading to discontinuation/dose reduction: Congestive cardiomyopathy Sources: |
90 mg single, oral Highest studied dose Dose: 90 mg Route: oral Route: single Dose: 90 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Congestive cardiomyopathy | Disc. AE | 210 mg 3 times / day multiple, oral Higher than recommended Dose: 210 mg, 3 times / day Route: oral Route: multiple Dose: 210 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Benfluorex and unexplained valvular heart disease: a case-control study. | 2010-04-12 |
|
| Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database. | 2010-03 |
|
| Role of substance P on histamine H(3) antagonist-induced scratching behavior in mice. | 2006-04 |
|
| Amphetamine-like stimulant cessation in an abusing patient treated with bupropion. | 2004-01 |
|
| Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. | 2002-05 |
|
| Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. | 2002-04 |
|
| Amphetamine, clobenzorex, and 4-hydroxyclobenzorex levels following multidose administration of clobenzorex. | 2001-04 |
|
| Clobenzorex: evidence for amphetamine-like behavioral actions. | 1997-02 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:48:52 GMT 2025
by
admin
on
Mon Mar 31 18:48:52 GMT 2025
|
| Record UNII |
BC6X5MB664
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
BC6X5MB664
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
m3627
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB01345MIG
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
5843-53-8
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
DTXSID0046145
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
C000490
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
DBSALT002797
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
71314913
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
236205
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000087932
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
227-434-5
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |